Evidence map›Paper›PMID 30954469›Full record

Observational studyAmerican journal of ophthalmology2019

Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema.

Mustafa Iftikhar, Tahreem A Mir, Gulnar Hafiz, Ingrid Zimmer-Galler, Adrienne W Scott, Sharon D Solomon, Akrit Sodhi, Adam S Wenick, Catherine Meyerle, Kim Jiramongkolchai and 6 more

Open access · greenAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Retinal vascular occlusions.Lancet (London, England) · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Low risk to retina from sustained suppression of VEGF.The Journal of clinical investigation · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Mustafa IftikharWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Tahreem A MirWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Gulnar HafizWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Ingrid Zimmer-GallerWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Adrienne W ScottWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Sharon D SolomonWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Akrit SodhiWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Adam S WenickWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Catherine MeyerleWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Kim JiramongkolchaiWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
T Y Alvin LiuWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
J Fernando ArevaloWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Mandeep SinghWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Saleema KheraniWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
James T HandaWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Peter A CampochiaroWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA. Electronic address: pcampo@jhmi.edu.
Johns Hopkins University · US

Funding

Promotion of retinal vascular hyperpermeability and macular edema by ANGPTL4R01EY025705 · NEI · UNIVERSITY OF MARYLAND BALTIMORE · PI MONTANER, SILVIA V · 2016 to 2020
$2.6M
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal DiseaseR01EY029750 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2019 to 2023
$2.6M
NEI NIH HHS R01 EY025705NEI NIH HHS R01 EY029750
6 · The paper itself

Abstract

purposeTo evaluate long-term visual and anatomic outcomes in patients with retinal vein occlusion (RVO) treated with anti-vascular endothelial growth factor (VEGF) agents.

designProspective, interventional case series.

participantsPatients with central RVO (CRVO) or branch RVO (BRVO).

methodsNumber of anti-VEGF injections and improvement from baseline best-corrected visual acuity (BCVA) and central subfield thickness (CST) were prospectively recorded in 40 eyes of 39 CRVO patients and 50 eyes of 47 BRVO patients.

resultsMean follow-up was 58 months for BRVO and 78 months for CRVO. Within 6 months of last follow-up, 58% of BRVO patients and 75% of CRVO patients required anti-VEGF injections to control edema. Analysis of the course of each patient over time showed that for BRVO patients, BCVA letter score increased by a mean of 24, from baseline of 52 (20/100) to peak of 76 (20/32), and subsequently decreased by 13, to 63 (20/50), at final visit; and for CRVO patients, BCVA letter score increased by a mean of 26, from baseline of 48 (20/100) to peak of 74 (20/32), and subsequently decreased by 18, to 56 (20/80), at last follow-up. Loss from peak BCVA occurred primarily owing to persistent/recurrent edema and related foveal damage.

conclusionsPatients with RVO showed large improvements in BCVA after initiation of anti-VEGF injections, but in many patients some visual gains were lost over time owing to bouts of recurrent edema. Sustained suppression of VEGF may help to provide optimal outcomes in RVO and reduce treatment burden.

Indexed as

Macular EdemaRanibizumabRetinal Vein OcclusionVisual AcuityAngiogenesis InhibitorsClinical Trials as TopicDisease ProgressionFollow-Up StudiesHumansIntravitreal InjectionsPilot ProjectsProspective StudiesTime FactorsVascular Endothelial Growth Factor AAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Identifiers

PMID30954469
PMCPMC10019499
OpenAlexW2925601565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.